Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | PDE6D | O43924 | 1/20 | 0.34 |
| ▸ | PDE6A | P16499 | 1/20 | 0.34 |
| ▸ | PDE6G | P18545 | 1/20 | 0.34 |
| ▸ | PDE6B | P35913 | 1/20 | 0.34 |
| ▸ | PDE6C | P51160 | 1/20 | 0.34 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984544 | 0.89 | F2RL3 (0.43) | MEN1GAAKMT2ANPC1RAB9A | |
| SCHEMBL2931660 | 0.86 | LMNA (0.51) | MEN1KMT2ALMNANPC1RAB9A | |
| SCHEMBL2965257 | 0.74 | KDM4E (0.41) | MEN1GAAKMT2AHSD11B1PDE2A | |
| SCHEMBL5420498 | 0.68 | KMT2A (0.47) | MEN1GAAKMT2AHSD11B1PDE2A | |
| SCHEMBL30856631 | 0.67 | — | — | |
| SCHEMBL24387038 | 0.65 | ALDH1A1 (0.31) | — | |
| SCHEMBL24386981 | 0.65 | — | — | |
| SCHEMBL2930344 | 0.64 | KIT (0.38) | MEN1KMT2AF2RL3 | |
| SCHEMBL2025862 | 0.64 | ADORA2A (0.47) | LMNANPC1RAB9AHSD11B1PDE2A | |
| SCHEMBL15369650 | 0.63 | LMNA (0.50) | KMT2ALMNANPC1RAB9AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | MEN1 2668/4885GAA 1559/4885KMT2A 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.